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Abstract 
For the pig respiratory tract pathogens, Actinobacillus pleuropneumoniae and Pasteurella 
multocida, Minimum Inhibitory Concentration (MIC) of marbofloxacin was determined in 
recommended broths and pig serum at three inoculum strengths. MICs in both growth 
matrices increased progressively from low, through medium to high starting inoculum counts, 
10
4
, 10
6
 and 10
8
 CFU/mL, respectively. P. multocida MIC ratios for high:low inocula were  
14:4:1 for broth and 28.2:1 for serum. Corresponding MIC ratios for A. pleuropneumoniae 
were lower, 4.1:1 (broth) and 9.2:1 (serum). MIC high:low  ratios  were therefore both 
growth matrix and bacterial  species dependent. The effect of alterations to the chemical 
composition of broths and serum on MIC were also investigated. Neither adjusting broth or 
serum pH in six increments over the range 7.0 to 8.0 nor increasing calcium and magnesium 
concentrations of broth in seven incremental steps significantly affected MICs for either 
organism. In time-kill studies, the killing action of marbofloxacin had the characteristics of 
concentration dependency against both organisms in both growth matrices. It is concluded 
that MIC and time-kill data for marbofloxacin, generated in serum, might be preferable to 
broth data, for predicting dosages of marbofloxacin for clinical use.    
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1. Introduction 
The most widely used parameter of antimicrobial drug potency is Minimum Inhibitory 
Concentration (MIC). This is the lowest (fixed) drug concentration which inhibits bacterial 
growth in vitro under standard conditions, after incubation for a fixed time.  Guidelines and 
standards have been set by the European Union Committee on Antimicrobial Sensitivity 
testing (EUCAST) and the Clinical Laboratory Standards Institute (CLSI). Their methods 
require use of a specific broth for each organism (formulated to facilitate /optimise bacterial 
growth) and are conducted using two-fold dilutions. Each test incorporates control organisms 
of known MIC. The adoption of CLSI and EUCAST guidelines and standards ensures that 
data generated is consistent between individual experimenters, between laboratories and 
across countries (Papich 2013). From a clinical use perspective, the principal objective in 
generating MIC data for each drug against each pathogenic organism harvested from each 
animal species is its application to determine dosage regimens that optimise bacterial kill and 
minimise opportunities for the emergence of resistance.  For this purpose the following 
considerations are paramount: 
 EUCAST and CLSI standardised MIC data are generated in broths, such as Cation 
Adjusted Mueller Hinton Broth (CAMHB), each formulated to facilitate growth in 
vitro, the composition differing (for some constituents markedly) from biological 
fluids in general and from the biophase in particular, in respect of chemical, 
immunological and cellular constituents, so that they might not be representative of 
bacterial growth conditions in vivo; 
 EUCAST and CLSI standardised MICs are determined using two-fold dilutions and 
are subject to good precision but potentially high inaccuracy - for an isolate MIC of 
say 4 µg/mL, the next lower MIC is 2 µg/mL and the “true” MIC might be 2.01 
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µg/mL; from dose determination perspectives it is accuracy rather than which is 
required; 
 MICs provide a measure of potency for a fixed concentration over a fixed time period, 
whereas in clinical use drug concretions decrease steadily after intravenous 
administration or increase to a maximum and then decrease, as absorption is balanced 
by elimination after non-vascular dosing; 
 MIC gives no indication of the time course of killing action , which may be 
concentration-, time- or co-dependent and this killing pattern may differ for a single 
drug against differing microbial species; 
 MIC is determined using a fixed inoculum count of 5x105 CFU/mL under EUCAST 
and CLSI guidelines, whilst bacterial load, on which rate and extent of bacterial kill is 
likely to depend, may be much higher or lower and vary with time in vivo; 
 in vivo, in diseased but immunocompetent animals, bacteriological cure will be 
assisted by natural body defences. 
To partially address the above considerations, in relation to correlating pharmacokinetic and 
pharmacodynamic data to predict dosages, we have used five sets of overlapping two-fold 
dilutions in previous studies; this reduces the inaccuracy from approaching 100% to not 
exceeding 20% (Aliabadi and Lees, 2001; Sidhu et al., 2010). Also, to enable comparisons 
between broth and biological fluids, as growth matrices for bacteria, and to evaluate possible 
differences between them, previous studies have been undertaken in serum, plasma and 
inflammatory exudate (Aliabadi and Lees, 2001, 2002; Nightingale and Murakawa 2002; 
Zeitlinger et al., 2004, 2008, 2011; Sidhu et al., 2010). A future development might be 
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generation of MIC data in biophase fluids, which might be serum, urine (of varying pH), 
milk, prostate and pulmonary epithelial lining fluid etc.,   
For some drug classes, potency differences between broths and biological fluids are small and 
have no significant impact on dose prediction; provided the inactive protein bound 
plasma/serum drug concentration is known and corrected for. For other drug classes, 
however, differences between broths and biological fluids may be large. In a recent study, 
several tetracyclines were compared for MICs in broth and 50% broth:50% mouse serum as 
matrices (Honeyman et al., 2015).  For a strain of Strep. pneumoniae, MICs were identical for 
five compounds but, with added serum, 2-4 fold increases were obtained for five further 
compounds, and MIC was increased 32-fold for one compound. In contrast, for a strain of 
Staph. aureus, MIC was increased in the broth:serum combined matrix relative to broth for 
all 12 compounds investigated and for seven the increase was in the range 8-128-fold. 
Likewise, Brentnall et al. (2012) reported for a calf isolate of Mannheimia haemolytica a 
MIC in serum 19 times greater than the broth MIC for oxytetracycline. In contrast, Illambas 
et al. (2009) and Toutain et al. (2016) reported MICs some 50-fold smaller in calf serum 
compared to broth for tulathromycin for Mannheimia haemolytica and Pasteurella multocida 
isolates from calves, and this difference was some 80-fold when serum values were corrected 
for protein binding. Zeitlinger et al. (2011) have proposed “in order to be able to extrapolate 
data from various models to in vivo situations, models should always attempt to mimic 
physiological conditions as closely as possible”. Hence, the quantitative determination of 
pharmacodynamic indices with improved accuracy and in biological matrices should be 
regarded, for some drug classes, as appropriate in applying PK/PD integration and modelling 
methods to dose determination. 
To optimise clinical efficacy and minimise the emergence of resistance to antimicrobial 
drugs, a further consideration is dosage required for differing pathogen loads. For 
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metaphylaxis and treatment early in the course of disease, when the pathogen load is low or 
absent, many drugs, at recommended dose rates, will prevent or cure disease, in support of 
natural body defences. The major challenge for antimicrobial drugs, however, is to provide a 
bacteriological cure and avoid emergence of resistance, when pathogen numbers in the 
biophase are high. For this reason, a high starting inoculum count of approximately 
10
7
cfu/mL was selected for use in this study, in preference to the inoculum count of 
5x10
5
cfu/mL recommended in CLSI and EUCAST guidelines. 
The aims of this investigation were: (1) for marbofloxacin and six isolates each of 
Actinobacillus pleuropneumoniae and P. multocida (respiratory pathogens in the pig) to 
compare MICs in two matrices, CLSI recommended broths and pig serum, with  levels of 
inoculum count, low, intermediate and high; (2) for two isolates of each species to investigate 
the effect on  MIC of (a) varying the initial inoculum pH of serum and broth over the range 
7.0 to 8.0, (b) increasing the calcium and magnesium concentrations of broth and (c) addition 
of serum to broth in varying proportions; (3) to establish time-kill curves in serum and broth 
for six isolates A. pleuropneumoniae and P. multocida of eight multiples of MIC.  
 
2. Materials and Methods 
2.1 Bacterial isolates 
Twenty isolates of P. multocida were supplied by Don Whitley Scientific (Shipley, West 
Yorkshire, BD173SE, UK). This company also supplied three ATCC reference strains for use 
in all MIC tests; A. pleuropneumoniae ATCC 27090, Enterococcus faecalis ATCC 29212and 
E.coli ATCC 25922. Eight isolates of A. pleuropneumoniae were supplied by A. Rycroft 
(Royal Veterinary College, Hatfield, Herts., UK). All isolates were derived from EU field 
cases of pig pneumonia. They were stored at -80
o
C in 10% Marvel
®
 milk powder, 15% 
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glycerol in sterile distilled water. The mixture was sterilized by boiling for 5sec, left to cool 
for 12h and then boiled again for a further 5sec.  
Six isolates of each species were selected, based on three criteria: (1) ability to grow 
logarithmically in both CLSI recommended broth and pig serum; (2) susceptibility to 
marbofloxacin, as indicated by MIC determined using two-fold dilutions; and (3) then, 
selection of isolates with the highest and lowest broth MICs plus four randomly selected 
isolates with intermediate MICs. This pre-selection procedure ensured that all isolates could 
be used in further MIC and time-ill investigations in broth and serum.  
2.2 Culture methods and bacterial counts 
For A. pleuropneumoniae, Chocolate Mueller Hinton Agar (CMHA) was used for growth on 
a solid medium and Columbia broth supplemented with 2µg/mL nicotinamide adenine 
dinucleotide (NAD) was the liquid broth. This was selected in preference to veterinary 
fastidious medium (VFM) as it was consistently better at supporting bacterial growth and 
without the formation of blood pellets in VFM determination of MIC endpoint was easier for 
user.   Mueller Hinton agar supplemented with 5% defibrinated sheep blood (MHA) was used 
to grow P. multocida and the liquid medium was CAMHB.  Organisms were incubated in a 
static incubator at 37
o
C for 18-24 h.   
Bacterial counts were determined by serial dilution and spot plate counts. Ten-fold or 100-
fold dilutions were carried out in Phosphate Buffered Saline. Three 10µL drops of the 
appropriate dilutions were dropped onto the agar surface and allowed to dry for 10min before 
incubating. After 24 h incubation, the mean CFU count for each 10µL was determined, 
multiplied by 100 and then multiplied by the dilution factor to obtain the original CFU/mL. 
2.3 Minimum Inhibitory Concentrations 
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MICs were determined by microdilution for six isolates each of A. pleuropneumoniae and P. 
multocida, in accordance with CLSI guidelines, except for (1) using five sets of overlapping 
two-fold serial dilutions to reduce inaccuracy of individual isolate estimates from up to 100% 
to not greater than 20%; (2) comparing serum with broth; (3) using Columbia broth 
supplemented with 2µg/mL nicotinamide adenine dinucleotide (NAD) as the liquid broth; 
and (4) use of starting inocula of three strengths. These were high (1.5.10
8
CFU/mL), medium 
(1.5.10
6
CFU/mL) and low (1.5.10
4
CFU/mL). A 0.5 McFarland standard was made to provide 
a count of 1.5x10
8
CFU/mL (high).  Two 1:10 dilutions provided a count of 1.5x10
6
CFU/mL 
(medium).  Two further 1:10 dilutions gave counts of 1.5x10
4
CFU/mL (low).  MICs were 
determined in broth and serum, for six isolates of each species, triplicate estimates per 
isolates.   
Marbofloxacin, media and culture were added successively to each well of 96-well plates and 
plates sealed and incubated statically at 37
o
C for 24h. Spot plate counts were prepared 
immediately after plate inoculation. Tests on each isolate were undertaken in triplicate. 
Control ATCC isolates were used at a count of 5x10
5
CFU/mL as per CLSI guidelines. A 
positive control well contained medium and pathogen only and a negative control contained 
medium and marbofloxacin solution. Blank controls contained medium only.   
2.4  Effect of varying pH  and  divalent cation concentrations on MIC 
Studies were conducted on two isolates each of P. multocida and A. pleuropneumoniae to 
investigate the influence on MIC of: (1) varying inoculum pH (broth and serum); (2) 
increased concentrations of Ca
++
 and Mg
++
 (broth). To determine the effect of pH on MIC, 
the starting pH was adjusted to 7.0, 7.2, 7.4, 7.6, 7.8 or 8.0, using hydrochloric acid (1M) or 
sodium hydroxide (1M).  
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Calcium and magnesium ion concentrations of CAMHB, to meet CLSI standards, are in the 
ranges 20 to 25 mg/L Ca
++ 
and 10 to 12.5 mg/L Mg
++
. The concentrations of these cations 
were increased by addition of CaCl2 and MgCl2 solutions with seven adjustments (increased 
cation concentrations (mg/L) : 1  (0mg Ca and 0mg Mg); 2 (5mg Ca and 3mg Mg); 3 (10mg 
Ca and 6mg Mg
)
; 4 (15mg Ca and 10mg Mg
)
; 5 (20mg Ca and 12mg Mg) ; 6 (25mg Ca and 
15mg; and 7 (30mg Ca and 18mg Mg
)
. This test was repeated for P. multocida and A. 
pleuropneumoniae, although it is noted that CAMHB is not the recommended broth for A. 
pleuropneumoniae. 
2.5 Time-kill curves 
Time-kill curves were generated for six isolates each of A. pleuropneumoniae and P. 
multocida in both broth and serum. Two to 3 colonies of each isolate were added to 5 mL 
broth or serum and incubated overnight in an orbital incubator. Fifty µL of culture were 
diluted 1:50 in pre-warmed broth or serum and incubated statically for 1 h at 37
o
C.  This was 
compared to a 0.5 McFarland Standard and diluted ten-fold to obtain the starting inoculum, 
consistent with MIC determinations, at 2x10
7
CFU/mL, and confirmed by colony counts. 
Concentrations comprising eight multiples of MIC (0.25, 0.5, 1, 1.5, 2, 4, 6 and 8x) were 
prepared in pre-warmed broth or serum.  Ten µL of culture were used to inoculate the 
dilutions to give a 1 mL final volume.   
Fifty µL of each culture were sampled and viability determined through serial dilution and 
spot plates at nine time points; 0, 0.25, 0.5, 0.75, 1, 2, 4, 8 and 24h.  No organism was added 
as a negative control, whereas in positive controls no drug was added.  Spot plates were 
examined for contamination and biochemical identification methods were applied for suspect 
colonies.  Measurements were conducted in triplicate for six isolates of both organisms in 
broth and serum. The lower limit of quantification (LLOQ) was 33CFU/mL. 
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2.6  Data analysis 
Data were recorded on Microsoft excel, processed using GraphPad Prism v6 and analysed 
using IBM SPSS Statistics 22 by Kruskal-wallis H with post-hoc Mann-Whitney U test. 
 
3. Results 
3.1 Influence of inoculum count on MIC 
MICs were inoculum size dependent for both organisms, increasing progressively with 
inoculum count, in both media (Tables 1 and 2). For P. multocida, MIC ratios high:low 
inocula were significant (P<0.001) for broth (14.4:1) and serum (28.2:1). Ratios high:medium 
inocula were also significant for both media, 7.21:1 (broth) and 11.2:1 (serum) (P<0.01). For 
A. pleuropneumoniae high:low inocula ratios were somewhat lower but also statistically 
significant (P<0.01) for broth (4.1:1) and serum (9.2:1). Ratios high:medium inocula were 
also significant for both media. 
The data revealed a second important effect of initial inoculum load on MICs. The 
serum:broth MIC ratio was higher for the high inoculum count (1.23:1) than for the low 
starting count for which the ratio was 0.63:1. 
3.2 Influence of pH and cation concentrations on MIC 
Alteration of pH over the range 7.0 to 8.0, in six increments, did not affect MICs for either P. 
multocida (Fig.1) or A. pleuropneumoniae (Fig.2) in either broth or serum. In broth, 
increasing concentrations of Ca
++
 and Mg
++ 
likewise did not significantly affect MICs for  
either organism (Fig.3).  
3.4 Time-kill curves  
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Time-kill curves for eight multiples of MIC for six isolates of each species are illustrated in 
Figs. 1 (P. multocida) and 2 (A. pleuropneumoniae). For P.multocida, there was progressive 
growth inhibition at 1.5 and 2xMIC in both media; 2xMIC produced a 3log10decrease in 
CFU/mL by 2-4 h.  In broth, concentrations at and above 4xMIC resulted in virtual 
eradication at 8h, and at 8xMIC by 24 h in serum. For A. pleuropneumoniae, the patterns of 
growth inhibition were very similar for both media; little inhibition occurred at 
concentrations less that 1xMIC but 4xMIC produced a 3-4log10 decrease in CFU/mL by 8 h 
in both media. Virtual eradication (< 33 CFU/mL) occurred in both media at 6xMIC by 8 h 
and at 8xMIC by 4 h. For both organisms, the action of marbofloxacin in both media was 
classed as concentration-dependent. 
 
4. Discussion 
A previous study from this laboratory reported no significant differences in MIC between 
broths and pig serum for the pig pneumonia pathogens, P. multocida and A. 
pleuropneumoniae (Dorey et al., submitted). However, when serum MICs were corrected for 
drug binding to serum protein, to allow for the fact that protein bound drugs are 
microbiologically inactive (Wise, 1986, Zeitlinger, 2011, Gonzalez, 2013) the unbound 
fraction MIC was approximately 0.5X the broth MIC. This finding indicated that potency was 
approximately twice as high (MIC lower) in serum compared with broth and therefore that 
correction for protein binding is necessary but not sufficient.  The data suggested that 
biological fluids such as serum might be more suitable for PK/PD integration and modelling 
procedures for predicting optimal doses, for example through establishing PK/PD 
breakpoints. 
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 In addition to protein binding, Zeitlinger et al. (2008) described another factor potentially 
accounting for differences in MIC between broths and serum, namely differing bacterial 
growth rates. They compared growth curves, in the absence of antimicrobial drugs, for 
Staphylococcus aureus and Pseudomonas aeruginosa in MHB, serum and varying 
proportions of serum admixed with MHB. For both species, logarithmic growth was slower 
in serum than broth. This might provide more rapid kill in serum for a given drug 
concentration, as a consequence  of a lesser microbial challenge. Slower growth rates in pig 
serum compared to broth for P. multocida and A. pleuropneumoniae were obtained for both 
species in pig serum compared to broth in our laboratory (Dorey et al., unpublished data). 
The above findings stimulated further research, now published in this article. It was clearly 
established that a high inoculum count (10
8
CFU/mL) increased broth MIC by some 14-fold 
for P. multocida compared to a low count of 10
4
CFU/mL.  Whilst differences might well be 
predictable, it is important to establish the magnitude of differences, if (as we intend) the data 
is to be used in PK/PD breakpoint and dose prediction studies for differing pathological 
loads.   Moreover, the difference was growth matrix dependent; the corresponding high:low 
ratio for serum MIC was 28-fold greater. This matrix dependency lends further weight to the 
rationale for conducting MIC studies in biological fluids rather than broths for the purpose of 
determining PK/PD breakpoints. Qualitatively, similar findings were obtained for A. 
pleuropneumoniae but quantitatively they were smaller; thus, high:low MIC ratios were 4.1:1 
(broth) and 9.2:1 (serum).  
As a further aspect of the data, illustrating the complexity of the interactions between load 
and matrix, one might note the serum/broth MIC ratios. These differed, depending on 
inoculum load. For both pathogens, the serum:broth MIC ratio was 1.23:1 for the high 
inoculum load and corresponding values  for the low load were 0.63:1 (P. multocida) and o 
0.55:1 (A. pleuropneumoniae).  
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In light of the above findings, the present study investigated two of many possible factors 
affecting MICs, in addition to inoculum load and logarithmic growth rate. For some drug 
classes (e.g. macrolides/triamilides) there is high pH dependency (Toutain et al., 2016) and 
for tetracyclines the potential for covalent binding to calcium and/or magnesium ions has 
been reported (Carlotti et al. (2012). Korz et al. (1995) suggested that microbial growth might 
be limited by acidic growth conditions.  In the present study, the growth medium became 
slightly more acidic during the logarithmic growth phase for both broth and serum (data not 
shown).   In this study, however, altering pH in increments of 0.2 units between pHs 7.0 and 
8.0 did not affect MIC for either organism and both growth matrices. Likewise, increasing in 
combination broth concentrations of Ca
++
 and Mg
++
 incrementally did not alter MICs.   
Finally, our data illustrate the importance of establishing not only the potency of drugs in 
MIC studies which use, under EUCAST and CLSI guidelines, exposure to constant 
concentrations for fixed time periods and  a single inoculum count in non-biological fluids, 
but also the potency in biological fluids and the time course of killing action. For 
marbofloxaxin, against the two pathogens studied, this was shown to be concentration-
dependent in serum as well as broth. Time courses of kill were similar but not identical and 
by 24 h, in both matrices at 2xMIC, 3.5-4log10 reductions in bacterial count had occurred. In 
future studies it would be relevant to extend these findings by evaluating level of kill at 48h 
and 72h and also rates of kill at even higher multiples of MIC (Mitchell et al. 2012). These 
investigations should now be extended to establish drug efficacy and potency with varying 
concentrations over time using, for example, hollow fibre infection models.  
In summary, the present data suggest that MIC values should be considered on drug-by-drug, 
matrix-by matrix, species-by-species and load-by-load bases, not only to allow for the 
inactive protein bound fraction but also to allow for the many in vitro differences that can be 
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applied, in combination with drug pharmacokinetics to prediction of dosage for use in disease 
models and then clinical trials.  
 
4. Summary 
Small but significant growth matrix dependent effects on MIC, MBC and MPCs were 
demonstrated for marbofloxacin for two pathogenic bacterial species harvested from pigs, 
A.pleuropneumoniae and P.multocida. For these indices of potency, correction of MIC serum 
data for drug protein binding revealed significant differences, whereby the active 
concentration (unbound serum concentration) was 2-fold lower than predicted, indicating that 
correction for drug binding to serum protein is necessary but not sufficient. For both growth 
media, the use of five overlapping sets of two-fold dilutions increased the accuracy of 
determinations.  For A.pleuropneumoniae and P.multocida, serum MPCs were 17-19 folds 
higher than MICs. Marbofloxacin was concentration-dependent in its killing action against 
both pathogens.   
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Table 1 
P. multocida broth and serum MICs for three inoculum strengths†, inoculum size ratios and 
serum:broth MIC ratios 
       Inoculum size Broth MIC Serum MIC Serum:broth ratio 
High 0.23 (0.06) 0.28 (0.07) 1.23 : 1 
Medium 0.03 (0.02) 0.03 (0.01) 0.79 : 1 
Low 0.02 (0.01) 0.01 (0.00) 0.63 : 1 
    
High:low ratio 14.4 :1 ** 28.2 : 1 **  
High:medium ratio 7.2 : 1 * 11.2 : 1 *  
Medium:low ratio 2.0 : 1 2.5 : 1  
†: High (1.5 x 108CFU/mL), medium (1.5 x 106CFU/mL) and low (1.5 x 104CFU/mL). MICs are 
geometric means (SD) of six isolates: triplicate analyses for each. Significant differences between 
inoculum strengths *P<0.01 **P<0.001. 
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Table 2 
A. pleuropneumoniae broth and serum MICs for three inoculum strengths†, inoculum size ratios and 
serum:broth MIC ratios 
Inoculum size Broth MIC Serum MIC Serum:Broth ratio 
High 1.91 (0.18) 2.34 (0.22) 1.23 : 1 
Medium 0.77 (0.11) 0.66 (0.05) 0.86 : 1 
Low 0.46 (0.04) 0.26 (0.02) 0.55 : 1 
    
High:low ratio 4.1 : 1** 9.2 : 1 **  
High:medium ratio 2.5 : 1* 3.5 : 1*  
Medium:low ratio 1.7 : 1 2.6 : 1  
†: High (1.5 x 108CFU/mL), medium (1.5 x 106CFU/mL) and low (1.5 x 104CFU/mL).  MICs are 
geometric means (SD) of six isolates: triplicate analyses for each. Significant differences between 
inoculum strengths: *P<0.05 **P<0.01. 
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Figure 1. MICs for two isolates of P. multocida (PM) in broth and serum adjusted to six pH 
values: means of two isolates and standard deviation for triplicate analyses. 
 
Figure 2. MICs for two isolates of A. pleuropneumoniae (APP) in broth and serum adjusted 
to six pH values: means of two isolates and standard deviation for triplicate analyses. 
 
Figure 3. Marbofloxacin  MICs (µg/mL):mean and standard deviation (triplicate  
analyses)for two isolates each of P.multocida and A.pleuropneumoniae in CAMHB with 
increased cation concentrations (mg/L) : 1 (0mg Ca and 0mg Mg); 2 (5mg Ca and 3mg Mg); 
3 (10mg Ca and 6mg Mg
)
; 4 (15mg Ca and 10mg Mg
)
; 5 (20mg Ca and 12mg Mg) ; 6 (25mg 
Ca and 15mg; and 7 (30mg Ca and 18mg Mg
)
.  
 
Figure 4. P. multocida growth inhibition over 24 h exposure to 8 multiples of MIC in (A) 
CAMHB and (B) serum (n=6). Bars=standard deviation. LLOQ= 33CFU/mL. 
 
Figure 5. A. pleuropneumoniae growth inhibition over 24 h exposure to 8 multiples of MIC 
in (A) Columbia broth supplemented with NAD and (B) pig serum (n=6). Bars=standard 
deviation. LLOQ= 33CFU/mL. 
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Figure 5  
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Part 2: Highlights 
 
 Minimum Inhibitory Concentration of marbofloxacin was both inoculum size and growth 
matrix dependent (broth/serum comparison) for the pig pathogens, P. multocida and A. 
pleuropneumoniae 
 Time-kill curves in broth and serum were concentration-dependent. 
